Inhibition of PD-1-PD-L1 immune checkpoint has showed effectiveness in colon cancer therapy but is still not used as the first-line treatment, as the lack of mechanism explorations and clinical experiments. This evidence concerns the gene PDCD1 and malignant colon neoplasm.